Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has proved helpful vigilantly but unsuccessfully to create an one off therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in terms of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be used is an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as a combination therapy in the therapy of multi-drug-resistant HIV are actually closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of the last few shares of mine. My 1st CytoDyn article, “CytoDyn: What To Do When It is Too Good In order to Be True?”, set away all of the following prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan offered such a highly marketing image in the Uptick Newswire employment interview which I came away with a bad impression of the company.

Irony of irony, the bad viewpoint of mine of the business enterprise has grown steadily, however, the disappointment hasn’t been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger yet still disappoints? Therein is the story; let me explain.

CytoDyn acquired its much storied treatment (which I shall relate to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the treatment as well as prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity of HIV infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of this expertise as well as linked intellectual property coming from Progenics to CytoDyn, and also approximately twenty five million mg of majority drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 million) as well as the very first new drug application endorsement ($5 million), as well as royalty payments of five percent of net sales after commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous therapies and numerous indications, it has this single treatment and a “broad pipeline of indications” as it places it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially beneficial therapy of dozens of indications.

Its opening banner on the site of its (below) shows an energetic organization with diverse interests albeit focused on leronlimab, several illness sorts, multiple delivering presentations in addition to multiple publications.

Could all of it be smoke cigarettes and mirrors? That’s a question I have been asking myself with the very start of the interest of mine in this particular business. Judging by the multiples of a huge number of various responses on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I am far from alone in this question.

CytoDyn is a classic battleground, or some may say cult inventory. Its adherents are fiercely protective of its prospects, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *